Regulatory Focus™ > News Articles > Spotlight on Drug Risks

Spotlight on Drug Risks

Posted 01 September 2009

Efforts by the US Food and Drug Administration (FDA) to strengthen risk disclosure and management have intensified, causing the pharmaceutical industry to rethink its approach to advertising and promotional labeling. This article provides an overview of the recent intensified efforts by FDA related to risk information for pharmaceutical drug products.


© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.